Mirum Ebitda vs Income Before Tax Analysis

MIRM Stock

USD 50.04 0.00 0.00%

Mirum Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Mirum Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mirum Pharmaceuticals is a good investment. Please check the relationship between Mirum Pharmaceuticals Ebitda and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Ebitda vs Income Before Tax

Ebitda vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mirum Pharmaceuticals Ebitda account and Income Before Tax. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Mirum Pharmaceuticals' Ebitda and Income Before Tax is 0.97. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Mirum Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Mirum Pharmaceuticals' Ebitda and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Mirum Pharmaceuticals are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Ebitda i.e., Mirum Pharmaceuticals' Ebitda and Income Before Tax go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebitda

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Mirum Pharmaceuticals income statement and is an important metric when analyzing Mirum Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Mirum Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mirum Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.At this time, Mirum Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 17th of February 2025, Tax Provision is likely to grow to about 856.2 K, while Enterprise Value Over EBITDA is likely to drop (8.51).

Mirum Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue
Total Assets		0.99	0.99	0.59	0.94	0.65	0.67	-0.97	0.82	0.9	0.88	-0.79	0.9	0.96	0.85	0.85	0.98	0.98	0.99	0.99	-0.79	0.97	-0.79	0.93	-0.95	-0.67
Other Current Liab	0.99		1.0	0.54	0.95	0.59	0.73	-0.98	0.83	0.85	0.87	-0.76	0.91	0.97	0.86	0.84	0.98	0.98	0.96	0.96	-0.76	0.93	-0.76	0.91	-0.96	-0.71
Total Current Liabilities	0.99	1.0		0.51	0.97	0.62	0.71	-0.98	0.86	0.83	0.88	-0.78	0.92	0.96	0.88	0.86	0.98	0.97	0.95	0.96	-0.78	0.93	-0.78	0.89	-0.97	-0.68
Total Stockholder Equity	0.59	0.54	0.51		0.41	0.07	0.64	-0.44	0.24	0.71	0.25	-0.17	0.49	0.69	0.21	0.29	0.51	0.65	0.65	0.57	-0.17	0.58	-0.17	0.77	-0.44	-0.17
Other Liab	0.94	0.95	0.97	0.41		0.63	0.7	-0.97	0.93	0.69	0.87	-0.8	0.89	0.9	0.9	0.91	0.96	0.92	0.86	0.9	-0.8	0.85	-0.8	0.77	-0.99	-0.54
Net Tangible Assets	0.65	0.59	0.62	0.07	0.63		-0.08	-0.67	0.75	0.56	0.82	-0.96	0.53	0.42	0.8	0.83	0.61	0.47	0.63	0.71	-0.96	0.72	-0.96	0.41	-0.64	-0.23
Net Debt	0.67	0.73	0.71	0.64	0.7	-0.08		-0.66	0.48	0.51	0.38	-0.17	0.7	0.84	0.42	0.41	0.71	0.81	0.62	0.58	-0.17	0.52	-0.17	0.74	-0.69	-0.52
Retained Earnings	-0.97	-0.98	-0.98	-0.44	-0.97	-0.67	-0.66		-0.9	-0.79	-0.93	0.82	-0.93	-0.91	-0.93	-0.91	-0.97	-0.94	-0.92	-0.94	0.82	-0.91	0.82	-0.84	0.99	0.66
Accounts Payable	0.82	0.83	0.86	0.24	0.93	0.75	0.48	-0.9		0.53	0.88	-0.9	0.85	0.71	0.95	0.95	0.82	0.75	0.73	0.77	-0.9	0.73	-0.9	0.57	-0.93	-0.35
Cash	0.9	0.85	0.83	0.71	0.69	0.56	0.51	-0.79	0.53		0.74	-0.63	0.75	0.87	0.64	0.64	0.82	0.87	0.96	0.93	-0.63	0.94	-0.63	0.96	-0.73	-0.68
Cash And Short Term Investments	0.88	0.87	0.88	0.25	0.87	0.82	0.38	-0.93	0.88	0.74		-0.9	0.9	0.75	0.98	0.95	0.88	0.79	0.85	0.89	-0.9	0.88	-0.9	0.7	-0.92	-0.61
Common Stock Total Equity	-0.79	-0.76	-0.78	-0.17	-0.8	-0.96	-0.17	0.82	-0.9	-0.63	-0.9		-0.7	-0.59	-0.92	-0.92	-0.74	-0.64	-0.74	-0.8	1.0	-0.79	1.0	-0.54	0.81	0.36
Common Stock Shares Outstanding	0.9	0.91	0.92	0.49	0.89	0.53	0.7	-0.93	0.85	0.75	0.9	-0.7		0.88	0.9	0.86	0.9	0.9	0.87	0.87	-0.7	0.84	-0.7	0.82	-0.95	-0.63
Non Current Liabilities Total	0.96	0.97	0.96	0.69	0.9	0.42	0.84	-0.91	0.71	0.87	0.75	-0.59	0.88		0.73	0.73	0.95	1.0	0.95	0.93	-0.59	0.9	-0.59	0.96	-0.9	-0.68
Capital Surpluse	0.85	0.86	0.88	0.21	0.9	0.8	0.42	-0.93	0.95	0.64	0.98	-0.92	0.9	0.73		0.97	0.86	0.77	0.79	0.85	-0.92	0.82	-0.92	0.64	-0.94	-0.52
Other Current Assets	0.85	0.84	0.86	0.29	0.91	0.83	0.41	-0.91	0.95	0.64	0.95	-0.92	0.86	0.73	0.97		0.87	0.77	0.79	0.86	-0.92	0.84	-0.92	0.64	-0.93	-0.39
Other Stockholder Equity	0.98	0.98	0.98	0.51	0.96	0.61	0.71	-0.97	0.82	0.82	0.88	-0.74	0.9	0.95	0.86	0.87		0.97	0.94	0.96	-0.74	0.94	-0.74	0.88	-0.96	-0.65
Total Liab	0.98	0.98	0.97	0.65	0.92	0.47	0.81	-0.94	0.75	0.87	0.79	-0.64	0.9	1.0	0.77	0.77	0.97		0.96	0.94	-0.64	0.92	-0.64	0.95	-0.93	-0.69
Net Invested Capital	0.99	0.96	0.95	0.65	0.86	0.63	0.62	-0.92	0.73	0.96	0.85	-0.74	0.87	0.95	0.79	0.79	0.94	0.96		0.99	-0.74	0.98	-0.74	0.96	-0.88	-0.68
Total Current Assets	0.99	0.96	0.96	0.57	0.9	0.71	0.58	-0.94	0.77	0.93	0.89	-0.8	0.87	0.93	0.85	0.86	0.96	0.94	0.99		-0.8	1.0	-0.8	0.92	-0.91	-0.66
Capital Stock	-0.79	-0.76	-0.78	-0.17	-0.8	-0.96	-0.17	0.82	-0.9	-0.63	-0.9	1.0	-0.7	-0.59	-0.92	-0.92	-0.74	-0.64	-0.74	-0.8		-0.79	1.0	-0.54	0.81	0.36
Net Working Capital	0.97	0.93	0.93	0.58	0.85	0.72	0.52	-0.91	0.73	0.94	0.88	-0.79	0.84	0.9	0.82	0.84	0.94	0.92	0.98	1.0	-0.79		-0.79	0.91	-0.88	-0.64
Common Stock	-0.79	-0.76	-0.78	-0.17	-0.8	-0.96	-0.17	0.82	-0.9	-0.63	-0.9	1.0	-0.7	-0.59	-0.92	-0.92	-0.74	-0.64	-0.74	-0.8	1.0	-0.79		-0.54	0.81	0.36
Short Long Term Debt Total	0.93	0.91	0.89	0.77	0.77	0.41	0.74	-0.84	0.57	0.96	0.7	-0.54	0.82	0.96	0.64	0.64	0.88	0.95	0.96	0.92	-0.54	0.91	-0.54		-0.8	-0.71
Property Plant And Equipment Net	-0.95	-0.96	-0.97	-0.44	-0.99	-0.64	-0.69	0.99	-0.93	-0.73	-0.92	0.81	-0.95	-0.9	-0.94	-0.93	-0.96	-0.93	-0.88	-0.91	0.81	-0.88	0.81	-0.8		0.58
Current Deferred Revenue	-0.67	-0.71	-0.68	-0.17	-0.54	-0.23	-0.52	0.66	-0.35	-0.68	-0.61	0.36	-0.63	-0.68	-0.52	-0.39	-0.65	-0.69	-0.68	-0.66	0.36	-0.64	0.36	-0.71	0.58

Click cells to compare fundamentals

Mirum Pharmaceuticals Account Relationship Matchups

Mirum Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	240.9M	294.7M	352.9M	646.6M	743.6M	780.8M
Other Current Liab	14.0M	32.0M	54.2M	78.5M	90.3M	94.8M
Total Current Liabilities	18.5M	42.6M	64.7M	87.1M	100.1M	105.1M
Total Stockholder Equity	(173.2M)	120.2M	(392.8M)	248.7M	286.0M	300.3M
Other Liab	36K	47.7M	129.9M	144.9M	166.6M	174.9M
Net Tangible Assets	130.3M	172.1M	101.5M	83.1M	95.5M	103.3M
Net Debt	(138.8M)	(28.7M)	(25.8M)	21.8M	25.1M	26.3M
Retained Earnings	(173.2M)	(257.2M)	(392.8M)	(556.2M)	(500.6M)	(475.6M)
Accounts Payable	3.2M	9.2M	8.7M	7.4M	8.5M	5.9M
Cash	142.1M	31.3M	28.0M	286.3M	329.3M	345.7M
Non Current Assets Total	4.5M	128.1M	162.7M	259.1M	297.9M	312.8M
Non Currrent Assets Other	1.3M	101.8M	101.4M	4.2M	4.8M	4.6M
Other Assets	3.2M	101.8M	101.4M	1.0	1.15	1.09
Cash And Short Term Investments	231.8M	156.5M	251.7M	286.3M	329.3M	205.0M
Common Stock Shares Outstanding	25.3M	30.3M	33.8M	40.9M	47.0M	32.3M
Liabilities And Stockholders Equity	(104.4M)	294.7M	(182.0M)	646.6M	743.6M	780.8M
Non Current Liabilities Total	50.3M	131.8M	146.1M	310.9M	357.5M	375.4M
Capital Surpluse	200.1M	345.2M	377.4M	535.1M	615.3M	320.7M
Capital Lease Obligations	3.3M	2.6M	2.2M	1.7M	2.0M	2.5M
Other Current Assets	9.1M	10.5M	8.9M	10.9M	12.6M	7.7M
Other Stockholder Equity	345.2M	377.4M	535.1M	803.3M	923.7M	969.9M
Total Liab	68.8M	174.4M	210.9M	398.0M	457.6M	480.5M
Net Invested Capital	172.1M	120.2M	142.0M	555.1M	638.4M	670.3M
Property Plant And Equipment Gross	3.2M	2.6M	2.3M	2.0M	2.3M	2.5M
Total Current Assets	236.4M	166.6M	190.2M	387.5M	445.7M	468.0M
Accumulated Other Comprehensive Income	83K	(35K)	(217K)	1.6M	1.9M	2.0M
Non Current Liabilities Other	50.3M	131.8M	146.1M	3.8M	4.4M	4.2M
Net Working Capital	217.9M	124.0M	125.5M	300.5M	345.5M	362.8M
Short Term Debt	1.3M	1.4M	1.9M	1.1M	1.3M	1.1M
Property Plant Equipment	3.7M	1.3M	981K	914K	822.6K	1.1M
Short Long Term Debt Total	3.3M	2.6M	2.2M	308.1M	354.4M	372.1M
Property Plant And Equipment Net	3.2M	2.6M	2.3M	2.0M	1.8M	2.2M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:

How To Invest In Mirum

Details

Is Mirum Stock a good investment?

Details

What is Mirum Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

6.513

Quarterly Revenue Growth

0.894

Return On Assets

(0.09)

Return On Equity

(0.40)

The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mirum Ebitda vs Income Before Tax Analysis

Ebitda vs Income Before Tax

Ebitda vs Income Before Tax Correlation Analysis

Correlation Coefficient

Ebitda

Income Before Tax

Mirum Pharmaceuticals fundamental ratios Correlations

Mirum Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mirum Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Capital Stock	+ 1.0	Common Stock Total Equity
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Net Working Capital	+ 1.0	Total Current Assets
Common Stock	+ 1.0	Capital Stock

Property Plant And Equipment Net	- 0.99	Other Liab
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Liab
Property Plant And Equipment Net	- 0.97	Total Current Liabilities